Clinical trial
B7451015
Name
B745
Description
Provide pre-approval single patient Expanded Access (compassionate use) of abrocitinib for patients with severe uncontrolled atopic dermatitis
Trial arms
Treatment
abrocitinib
Size
-1
Eligibility criteria
Must have severe uncontrolled atopic dermatitis refractory to other available treatments
Protocol
{'studyType': 'EXPANDED_ACCESS', 'nPtrsToThisExpAccNctId': 1, 'expandedAccessTypes': {'individual': True}}
Updated at
2023-11-15
1 organization
3 products
3 indications
Organization
PfizerProduct
AbrocitinibIndication
DermatitisIndication
AtopicProduct
PlaceboProduct
abrocitinibIndication
Atopic Dermatitis